A Multicentre, Prospective, Randomized, Open Label, Blinded-Endpoint, Placebo-controlled, Single-dose Trial to Determine the Efficacy and Safety of NoNO-42 in Participants With Acute Ischemic Stroke Selected for Thrombolysis With or Without Endovascular Thrombectomy (ACT-42 Trial)
Latest Information Update: 18 Nov 2024
At a glance
- Drugs NoNO 42 (Primary)
- Indications Ischaemic stroke
- Focus Therapeutic Use
- Acronyms ACT-42
- Sponsors NoNO
Most Recent Events
- 12 Nov 2024 Status changed from not yet recruiting to recruiting.
- 10 May 2024 New trial record